Kilambi News
Thursday, November 19, 2026

Archive

Every story, newest first.

Saturday, November 14, 2026

Life Sciences

Regeneron antibody cuts standing heart rate surge in POTS trial

Regeneron's baloncibart cut the lying to standing heart rate rise by 11.4 beats per minute versus placebo at day 8 in the 82 patient Phase 2 PINNACLE trial in postural orthostatic tachycardia syndrome, and Regeneron plans a potentially pivotal Phase 3 in the first half of 2027.

Life Sciences

Novo files sickle cell pill etavopivat with FDA and EMA

Novo Nordisk submitted etavopivat, its once daily oral sickle cell therapy, to the FDA and the EMA on November 13, on Phase 3 data showing a 27 percent reduction in painful vaso-occlusive crises.

Life Sciences

Moderna readies cancer vaccine plant ahead of year end filing

Moderna says its Marlborough plant is on track and ready to make several thousand doses of intismeran autogene, its Merck partnered personalised cancer vaccine, as the companies prepare to file for FDA approval by the end of 2026.

Life Sciences

Milestone cuts costs 30 percent as Cardamyst sales reach 1 million

Milestone Pharmaceuticals reported Cardamyst net product revenue of 1.0 million dollars in the third quarter, up 73 percent from the second quarter, and announced cost measures cutting operating expenses by about 30 percent, including a headquarters workforce reduction of about 20 percent and the departure of its chief financial and chief medical officers.

Life Sciences

Kyverna completes first autoimmune CAR T filing with miv-cel BLA

Kyverna Therapeutics completed its rolling Biologics License Application for miv-cel in stiff person syndrome on November 12 and asked the FDA for priority review, in what it calls the first BLA for a CAR T cell therapy in autoimmune disease.

Life Sciences

CMS gives states six month hold harmless on Medicaid work rules

The Centers for Medicare and Medicaid Services told states on November 13 they may delay denying or terminating Medicaid coverage over the new work requirements until June 30, 2027, even though the requirements still take effect on January 1.

Infrastructure

HASI closes $500 million green junior subordinated notes offering

HA Sustainable Infrastructure Capital has sold $500 million of 7.850 percent green junior subordinated notes due 2057, under an underwriting agreement dated November 9, 2026 and filed with the SEC on November 13.

Infrastructure

FTC sues to block Covetrus $3.5 billion MWI acquisition

The Federal Trade Commission sued on November 13 to block Covetrus, owned by Clayton, Dubilier and Rice and TPG, from acquiring MWI Animal Health from Cencora for $3.5 billion, alleging the deal merges the two largest veterinary supply distributors in the United States.

Infrastructure

European fundraising rises as investment and exits fall sharply

European private equity and venture funds raised 67.6 billion euros in the first half of 2026, up 6 percent, while investment fell 35 percent to 43.1 billion euros and divestments dropped 40 percent to 13.2 billion euros, Invest Europe reported.

Infrastructure

Also notable: payments talks collapse, Afreximbank window, postal surcharge

CD&R and GTCR have walked away from early talks to take Global Payments private, Afreximbank has opened a $2 billion facility for African sub-sovereign borrowers, and the U.S. Postal Service wants to make an 11 percent fuel surcharge permanent from January 2027.